From OCR to AI The Future of Media and Image Analysis in eDiscovery
Episode 373 -- Christian Focacci on Current Developments in AI and Risk Management
CareYaya: A Revolutionary Approach to Elder Care
No Password Required: CEO of HACKERverse.ai, Disruptor of Cybersecurity Sales and Most Other Things
Brooklyn District Attorney Eric Gonzalez – Innovative Approach to Safety
JONES DAY TALKS®: Women in IP – AI and Copyright Law Need-to-Knows
Hilary Preston, Vice Chair at Vinson & Elkins, Discusses Energy Innovation: Protecting Your Intellectual Property Portfolio
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 228: Designing & Manufacturing Auto-Injectors with Kimberlee Steele of SHL Medical
Innovation in Compliance: Visionary Leadership with Jackson Calame
A Thermal Storage Revolution With Nis Benn, Hyme Energy — Battery + Storage Podcast
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 225: Cancer Care Access & Treatments with Dr. Sengar of Alabama Cancer Care
Building a Business at the Intersection of Neurodata and Innovation With Rob Cooley
Approach to Responsible AI
Creating Impact Through Innovation: Brandon Kashani on Leading Mission-Driven Startups
Bridging the Gap: How CivicReach is Revolutionizing Government Customer Service
Podcast — Drug Pricing: 2025 J.P. Morgan Healthcare Conference Takeaways and Outlook
Podcast — UK FinReg Focus Areas in 2025: Sectoral Trends
Taking the Pulse, A Health Care and Life Sciences Video Podcast | Episode 218: Artificial Intelligence in Drug Development with John Van Hoy of PPD & Thermo Fisher
Driving Towards Greater Transparency and Sustainability in the EV Market with Davide Giacobbe and ScoutIt
Crafting an Effective Law Firm Generative AI Policy for Responsible Business Use: On Record PR
On April 10, 2025, the US Food and Drug Administration (FDA) announced its intent to phase out the use of animal testing in the development of certain drugs and biologics. To help bring this “paradigm shift in drug...more
The US Food and Drug Administration (FDA) recently announced a strategic roadmap to phase out animal testing requirements for certain drug products, starting with monoclonal antibodies. This shift marks a significant change...more
The U.S. Food and Drug Administration (FDA) on April 10, 2025, announced a significant policy shift aimed at reducing its reliance on animal testing for drug development and incorporating new approach methodologies (NAMs)...more
The top legal issues in 2024 for the life sciences field reflect the complex and changing legal landscape that the industry is navigating, encompassing drug pricing, regulatory challenges, and broader societal and governance...more
President Biden signed an Executive Order on America’s Supply Chains, E.O. 14017, which initiates a 10-day period to review the strength of United States supply chains for four specific sectors. The purpose of the Executive...more